These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21821334)

  • 1. [Efficacy of mycophenolate associated with methotrexate as a maintenance treatment for systemic sclerosis-associated interstitial lung disease].
    Gonzalez-Nieto JA; Martin-Suarez IJ; Gil-Muñoz FL
    Arch Bronconeumol; 2011 Nov; 47(11):575. PubMed ID: 21821334
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
    Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
    Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
    Tashkin DP; Roth MD; Clements PJ; Furst DE; Khanna D; Kleerup EC; Goldin J; Arriola E; Volkmann ER; Kafaja S; Silver R; Steen V; Strange C; Wise R; Wigley F; Mayes M; Riley DJ; Hussain S; Assassi S; Hsu VM; Patel B; Phillips K; Martinez F; Golden J; Connolly MK; Varga J; Dematte J; Hinchcliff ME; Fischer A; Swigris J; Meehan R; Theodore A; Simms R; Volkov S; Schraufnagel DE; Scholand MB; Frech T; Molitor JA; Highland K; Read CA; Fritzler MJ; Kim GHJ; Tseng CH; Elashoff RM;
    Lancet Respir Med; 2016 Sep; 4(9):708-719. PubMed ID: 27469583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.
    Iudici M; Cuomo G; Vettori S; Bocchino M; Sanduzzi Zamparelli A; Cappabianca S; Valentini G
    Semin Arthritis Rheum; 2015 Feb; 44(4):437-44. PubMed ID: 25282395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new therapy for systemic sclerosis-associated interstitial lung disease.
    Kondoh Y
    Respir Investig; 2020 Jul; 58(4):227-229. PubMed ID: 32451295
    [No Abstract]   [Full Text] [Related]  

  • 6. Unusual association of systemic sclerosis and ankylosing spondylitis.
    Soledade CS; Sampaio-Barros PD; Samara AM; Marques-Neto JF
    Clin Rheumatol; 2005 Nov; 24(6):652-4. PubMed ID: 15338450
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunosuppression for interstitial lung disease in systemic sclerosis.
    Cappelli S; Guiducci S; Bellando Randone S; Matucci Cerinic M
    Eur Respir Rev; 2013 Sep; 22(129):236-43. PubMed ID: 23997050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST.
    Fathi N; Furst DE; Clements PJ
    Curr Rheumatol Rep; 2007 May; 9(2):144-50. PubMed ID: 17502045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies.
    Nannini C; West CP; Erwin PJ; Matteson EL
    Arthritis Res Ther; 2008; 10(5):R124. PubMed ID: 18937831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Systemic Sclerosis-related Interstitial Lung Disease: A Review of Existing and Emerging Therapies.
    Volkmann ER; Tashkin DP
    Ann Am Thorac Soc; 2016 Nov; 13(11):2045-2056. PubMed ID: 27560196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of systemic sclerosis-associated interstitial lung disease.
    Roofeh D; Jaafar S; Vummidi D; Khanna D
    Curr Opin Rheumatol; 2019 May; 31(3):241-249. PubMed ID: 30870216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of cyclophospamide in the treatment of interstitial lung disease associated with systemic sclerosis.
    Espinosa G; Simeón CP; Plasín MÁ; Xaubet A; Muñoz X; Fonollosa V; Cervera R; Vilardell M
    Arch Bronconeumol; 2011 May; 47(5):239-45. PubMed ID: 21458128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. David against Goliath: may we target and defeat interstitial lung disease in systemic sclerosis?
    Miniati I; Conforti ML; Guiducci S; Matucci Cerinic M
    Clin Exp Rheumatol; 2007; 25(2):169-71. PubMed ID: 17543137
    [No Abstract]   [Full Text] [Related]  

  • 14. Cyclophosphamide in scleroderma lung disease.
    Sullivan KM; McSweeney PA; Nash RA
    N Engl J Med; 2006 Sep; 355(11):1173-4; author reply 1174. PubMed ID: 16977701
    [No Abstract]   [Full Text] [Related]  

  • 15. Does high-dose extended course cyclophosphamide and methylprednisolone pulse therapy have a role in the management of systemic sclerosis-related interstitial lung disease?
    Abignano G; Bissell LA; Emery P; Del Galdo F; Buch MH
    Rheumatology (Oxford); 2016 Dec; 55(12):2273-2275. PubMed ID: 27744357
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances in immunosuppressive therapy.
    Marder W; McCune WJ
    Semin Respir Crit Care Med; 2007 Aug; 28(4):398-417. PubMed ID: 17764058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful use of intravenous cyclophosphamide pulse therapy for interstitial lung disease in a patient with systemic sclerosis on hemodialysis.
    Takahashi T; Asano Y; Sunaga R; Ichimura Y; Taniguchi T; Yamamoto M; Tamaki Z; Takekoshi T; Mitsui H; Sugaya M; Ohse T; Sato S
    J Dermatol; 2014 Jun; 41(6):533-5. PubMed ID: 24814462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide in scleroderma lung disease.
    Andreu JL; Silva L
    N Engl J Med; 2006 Sep; 355(11):1173; author reply 1174. PubMed ID: 16977700
    [No Abstract]   [Full Text] [Related]  

  • 19. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
    Ueda T; Sakagami T; Kikuchi T; Takada T
    Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppressive treatment of the pulmonary manifestations of progressive systemic sclerosis.
    Vallance DK; Lynch JP; McCune WJ
    Curr Opin Rheumatol; 1995 May; 7(3):174-82. PubMed ID: 7612408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.